Targepeutics Announces Strategic Investment from Yuvaan Tiwari Foundation to Support Advancement of GB13 into Clinical Trials for DIPG
'We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community,' said Sil Lutkewitte, CEO of Targepeutics. 'Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG.'
GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG. Preclinical data have shown promising efficacy, and the new funding will accelerate the operational steps required to initiate a first-in-human trial. The FDA's Rare Pediatric Disease Designation (RPDD) for GB13 earlier this year underscores its potential impact and makes Targepeutics eligible for a Priority Review Voucher (PRV), which could expedite regulatory review and further support clinical development.
The Yuvaan Tiwari Foundation, created in memory of Yuvaan Tiwari who lost his life to Diffuse Midline Glioma (DMG) at the age of 3, is committed to accelerating breakthrough research and clinical solutions for pediatric brain cancer.
'We lost our son to this disease, and we know what's at stake. This is more than an investment — it's a direct action toward changing the outlook for children with DMG,' said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. 'Our foundation is proud to support Targepeutics' bold and innovative treatment approach. This investment reflects our focus on advancing therapies with real potential to impact the lives of children facing this devastating disease.'
Targepeutics remains focused on pushing the boundaries of what's possible in pediatric oncology, and this new partnership brings it one step closer to delivering transformative care to the patients who need it most.
About Targepeutics
Targepeutics has an intellectual property portfolio including several issued patents and additional patents pending, focused on novel targeted oncology therapeutics and diagnostics. The company has been awarded Rare Pediatric Disease Designation for GB13 which complements the Orphan Drug Designation for malignant gliomas. The company is completing the required preclinical activities and expects to file an IND for a pediatric first-in-human clinical trial in 1st quarter of 2026. (targepeutics.com)
About Yuvaan Tiwari Foundation
The Yuvaan Tiwari Foundation was established in 2021 by Parvati and Satya Tiwari to honor the legacy of their son Yuvaan (Yuvi). At age two, Yuvi was diagnosed with an aggressive and fatal brain tumor called diffuse midline glioma (DMG). Yuvi fought DMG bravely for seven months. The Yuvaan Tiwari Foundation accelerates high-impact research to find a cure for DMGs and other fatal pediatric brain cancers, while supporting patients and families along their journey. (www.ytfoundation.org)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Are melatonin supplements safe for kids?
The first time your baby sleeps through the night seems unforgettable — like a hopeful promise of a more rested future — but as many parents (unfortunately) find out, that hope often ends up feeling more like a mirage. Sleep challenges are a common part of parenting, and they can look different from household to household — or even night to night. Whether your child struggles to fall asleep or stay asleep, you're not alone. And if you've ever found yourself searching "natural sleep aids for kids" at 1 a.m., chances are melatonin has popped up. Yet despite this supplement's growing popularity, you may be wondering whether melatonin supplements are actually safe for kids. Melatonin is a hormone that helps regulate the body's internal clock, and while it's often used by adults to help manage sleep disorders and insomnia, over-the-counter melatonin supplements have become increasingly popular for kids too. Whether it's due to travel challenges and disrupted schedules, insomnia or sleep difficulties linked to ADHD or autism, parents are increasingly interested in using melatonin supplements as a way to help their kids (and themselves) get much-needed rest. To help cut through the confusion — and save you another sleepless nighttime scroll — we spoke with three pediatric experts, including two doctors and a registered dietitian, about if and when melatonin might be helpful and what to know about dosing and safety before purchasing a supplement. A note on supplements The products included on this list are dietary supplements. Statements about these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not appropriate for everyone and may interact with other supplements or medications, so talk to your health care provider before adding a dietary supplement to your routine. Are melatonin supplements safe for children? The short answer is yes, though Dr. Michelle Caraballo, sleep medicine specialist at Children's Health, and Dr. Rupali Drewek, co-medical director of the Sleep Medicine Program at Phoenix Children's, agree that these products aren't appropriate or effective for all kids and should be used only short-term under medical supervision. "Melatonin is usually recommended for short-term use (typically two to six weeks) while behavioral interventions are established. If effective, it can be used intermittently as needed, but long-term daily use should be monitored by a health care provider," says Drewek. She also notes that because melatonin isn't habit-forming, it doesn't require tapering off. "That said, if a child has been using it regularly for months, slowly reducing the dose over one to two weeks can help [you] evaluate whether it's still necessary. Some families find when you gradually taper off from melatonin, it avoids abrupt changes in sleep quality. It's also a good time to reinforce consistent bedtime routines and healthy sleep habits," she says. As for who might benefit, research is ongoing but has mostly looked at the benefits (and safety) of melatonin for kids with certain conditions. "It can be helpful for specific conditions such as delayed sleep-wake phase disorder or sleep issues in children with autism or ADHD. However, it is not FDA-approved for pediatric use, and safety data for long-term use is limited," Drewek says. She also cautions that because dietary supplements aren't tested for label accuracy by the Food and Drug Administration (FDA), quality and dosing can vary greatly between products. What about toddlers? From transitioning out of the crib to starting nighttime potty training, sleep becomes a particularly tricky issue with toddlers. However, Caraballo cautions that these supplements should not be given to children under the age of 3. There simply isn't enough research to determine whether melatonin is safe or appropriate for 1- and 2-year-olds. How much melatonin is safe for kids? How much melatonin to give your child should ultimately be decided by your pediatrician. Here's a general idea of what dosing might look like, according to Drewek: Preschoolers (3–4 years): 1 mg School-age children (5–12 years): 1–3 mg Adolescents (13–18 years): up to 5 mg Keep in mind that your pediatrician may recommend different doses than what's listed above, or encourage starting with a lower dose and gradually increasing. "We ask parents to start with a low dosage, according to age, and carefully evaluate how effective it is. Many children respond to a low dose (1–5 milligrams) when taken 30 minutes before bedtime," says Caraballo. Drewek echoes the importance of starting low and slow, adding, "Higher doses don't always improve sleep and may increase side effects like morning grogginess or vivid dreams." Other factors to consider when choosing a melatonin supplement for kids Once you have the green light from your pediatrician to give your child a bedtime supplement, the next step is choosing a product. As with any supplement, there are a few key factors to keep in mind when making your decision: Age-appropriate dose: To provide a safe and effective dose, only give your child a melatonin supplement that's specifically formulated for their age. Supplement type: Melatonin supplements for kids come in a variety of types, including gummies, liquids, powders, chewables and dissolvable tablets. There are also soft gel options for adolescents. The best option is the one that your child can take safely, though some forms may be more readily absorbed than others. "We generally recommend liquid or oral dissolvable formulation over gummies because the absorption is more reliable with liquid and tablet forms," says Caraballo. Other active ingredients: Some kids' bedtime supplements include other ingredients, like magnesium or L-theanine. While safe for kids, it's best to talk with your pediatrician about whether these ingredients are necessary or appropriate for your child. Sweeteners and food dyes: Some brands add sweeteners and food dyes — natural or artificial — to make supplements more appealing to kids. Ideally, choose options with minimal added sugar and naturally derived flavors and colors, like those from fruit or vegetable juices and extracts. Third-party testing: "Several studies have shown that the amount of melatonin in a bottle can vary significantly from the amount listed on a label," says Caraballo. For this reason, it's important to choose a product made by a reputable brand that's ideally been tested for label accuracy by a trusted independent organization, like NSF or United States Pharmacopeia (USP). Potential side effects and safety concerns We probably sound like a broken record at this point, but research on melatonin in kids is limited, meaning there's still more that researchers and medical experts have to learn when it comes to safety. That said, short-term use of melatonin has not been linked with serious side effects in kids when taken in appropriate amounts. A 2024 review study published in the journal Children found that commonly reported side effects of melatonin supplements in kids include vivid dreams, nightmares and extreme tiredness. Still, this doesn't mean there aren't serious safety concerns. "Supplements should be treated like medications. It is important to discuss with your child's physician before starting a supplement, as some supplements can interact with other medications and may not be appropriate for all children. And just like medications, supplements should be stored in a locked cabinet out of the reach of children," says Caraballo. "Accidental ingestion of melatonin by children has led to a significant increase in ER visits in recent years, so proper storage is critical," adds Drewek. If you're concerned that your child consumed excessive amounts, call your pediatrician or another medical professional right away. Alternatives to melatonin "To help your child sleep well, the most important thing you can do is establish a bedtime routine — and be consistent. Maintain the same bedtime and wake time every day, including weekends and holidays. Kids really respond well to routine, so that their bodies know what to expect," says Caraballo. If your child is struggling to fall or stay asleep, start by checking their sleep environment. "Keep bedrooms cool, dark and quiet. Darkness cues the brain that it's time to sleep. A dim nightlight is fine for children who may not like total darkness," says Caraballo. Bedtime routines should also evolve as kids grow, notes Drewek. For toddlers and preschoolers, predictable steps like brushing teeth, reading and cuddling can create a sense of security. School-age kids benefit from screen-free wind-down time and consistent sleep schedules. And while teens may be harder to guide, encouraging them to leave phones outside the bedroom can help curb late-night scrolling. If the thermostat is set, screens are off, the sound machine is humming and your child's bedtime routine is solid — yet sleep is still a struggle — it might be time to consider other natural sleep aids for kids. Several companies offer melatonin-free supplements featuring ingredients like magnesium or L-theanine. "These ingredients may help promote relaxation and ease bedtime anxiety, especially in children who are sensitive to melatonin or don't tolerate it well. While they don't directly shift the circadian rhythm like melatonin, they can be useful for calming the nervous system," says Drewek. Just note that while these supplements may be more appropriate for long-term use — as long as you have the OK from your pediatrician — Caraballo recommends melatonin more often than other supplements because it "has better data supporting its use in children." Melatonin supplements for kids As a registered dietitian and mom of two, I know firsthand how challenging it can be to navigate the world of kids' supplements. To help, I reviewed 10 of the top melatonin products for kids, evaluating each on dose, ingredients and kid-friendly factors, like taste and texture. Here are three standout options to talk with your pediatrician about. FAQs Can a 3-year-old take melatonin? Yes, according to Caballo, melatonin can be given to a 3-year-old, though it's important to do so only under the recommendation of a pediatrician. How often can you give melatonin to a child? According to Drewek, melatonin supplements are typically recommended for just two to six weeks while other behavioral and bedtime strategies are established. That said, how frequently to give your child melatonin for sleep may vary and should be discussed with a pediatrician. Drewek also notes that while melatonin may be a useful tool for some kids, it doesn't replace the need for a consistent bedtime routine. "Sleep supplements should never replace healthy sleep habits, which are the foundation of good sleep," she says. Is melatonin addictive for kids? No, according to Caraballo, "[Melatonin] is not considered addictive, and discontinuation should not cause withdrawal symptoms." However, due to a lack of research on its safety and effectiveness, melatonin shouldn't be given to your child for more than a few weeks or months. Instead, it's important to work with a health care professional to identify the root cause of your child's sleep disturbances. What's a safe melatonin brand for children? There are several reputable brands offering melatonin supplements for kids, including OLLY, Natrol, Zarbee's, Mommy's Bliss and more. Look for products that are tested to ensure label accuracy, ideally by a third-party lab. Can diet affect kids' sleep? According to Katie Drakeford, board-certified pediatric registered dietitian, yes, your child's diet could be contributing to their sleep troubles. In particular, Drakeford notes that diets low in omega-3 fatty acids and vitamin D may negatively affect your child's sleep, though research on the benefits of supplementation is limited. Overall, no single food is likely to make or break your child's sleep quality. To support better rest, studies (like this 2023 review published in the journal Nutrients) suggest prioritizing a diet rich in fiber — especially fruits and vegetables — while limiting foods high in saturated fat. Meet our experts Michelle Caraballo, MD, pediatric pulmonologist and sleep medicine specialist at Children's Health Rupali Drewek, MD, co-medical director of the Sleep Medicine Program at Phoenix Children's Katie Drakeford, board-certified pediatric registered dietitian Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
Medscape
4 days ago
- Medscape
Inhaled Isoflurane Matches Midazolam in Critically Ill Kids
TOPLINE: Inhaled isoflurane demonstrated noninferior sedation efficacy compared with intravenous midazolam in critically ill children aged 3-17 years on mechanical ventilation, while also lowering opioid requirements and time to extubation along with maintaining an acceptable safety profile. METHODOLOGY: Amid safety concerns over intravenous midazolam, inhaled isoflurane has emerged as an alternative sedative for critically ill patients requiring mechanical ventilation. However, supporting evidence remains limited. Researchers conducted a randomized phase 3 trial (IsoCOMFORT) across multiple pediatric ICUs to assess whether inhaled isoflurane was noninferior to intravenous midazolam as an alternate sedative strategy. They included 92 children who were critically ill and required invasive mechanical ventilation and sedation for ≥ 12 hours. They were randomly assigned to either inhaled isoflurane (n = 59; mean age, 8.1 years; 63% boys) or intravenous midazolam (n = 33; mean age, 7 years; 61% boys). At baseline after randomization, depth of sedation was assessed using the COMFORT Behavior scale, and children were assigned to light (score, 17-22), moderate (score, 11-16), or deep (score, 6-10) sedation target. Sedatives were titrated accordingly for up to 48 ± 6 hours during the treatment period. The primary outcome was the percentage of time maintaining adequate sedation within prescribed COMFORT Behavior scale target range — without rescue sedation, assessed every 2 hours over 12-48 hours. TAKEAWAY: Isoflurane maintained sedation within the COMFORT Behavior target range for a greater proportion of time (68.94%) than midazolam (62.37%), with a mean difference of 6.57 percentage points (95% CI, -8.99 to 22.13), confirming isoflurane's noninferiority to midazolam. The opioid requirements were lower in the isoflurane group (least squares mean dose, 2.1 μg/kg/h) than in the midazolam group (least squares mean dose, 4.6 μg/kg/h; P = .0004). Additionally, the time for extubation was significantly shorter with isoflurane (median, 0.75 hours) than with midazolam group (median, 1.09 hours). One child in each arm experienced treatment-related severe hypotension; three children receiving isoflurane discontinued due to adverse events, however, there were no treatment-related deaths. IN PRACTICE: 'Based on [the study] results and on the regulatory support from the EMA [European Medicines Agency], inhaled sedation can be regarded as a therapeutic option for sedation during mechanical ventilation in pediatric intensive care,' the authors of the study wrote. SOURCE: This study was led by Jordi Miatello, PhD, from the IHU-SEPSIS Comprehensive Sepsis Centre and Paediatric Intensive Care in Le Kremlin-Bicêtre, France, and Alba Palacios-Cuesta, MD, from the 12 de Octubre University Hospital in Madrid, Spain. It was published online on July 15, 2025, in The Lancet Respiratory Medicine. LIMITATIONS: This study excluded children younger than 3 years, limiting the generalizability of the findings to younger pediatric ICU patients. The choice of inhaled sedative, as sevoflurane has replaced isoflurane for general anesthesia in many countries. Lastly, masking only the COMFORT Behavior assessor, rather than the entire clinical team, could lead to bias in outcome assessment. DISCLOSURES: This study was funded by Sedana Medical, Stockholm, Sweden. Few authors received honoraria from the funding organization for participation in the IsoCOMFORT Study Steering Committee. Two authors were employees of the funding organization. Two authors also reported being consultant with other pharmaceutical organizations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
24-07-2025
- Yahoo
Targepeutics Announces Strategic Investment from Yuvaan Tiwari Foundation to Support Advancement of GB13 into Clinical Trials for DIPG
HUMMELSTOWN, Pa., July 24, 2025--(BUSINESS WIRE)--Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, is proud to announce a strategic financing round led by the Yuvaan Tiwari Foundation. This investment will directly support the advancement of GB13, Targepeutics' lead drug candidate, into clinical trials for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) — one of the deadliest pediatric brain tumors. "We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community," said Sil Lutkewitte, CEO of Targepeutics. "Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG." GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG. Preclinical data have shown promising efficacy, and the new funding will accelerate the operational steps required to initiate a first-in-human trial. The FDA's Rare Pediatric Disease Designation (RPDD) for GB13 earlier this year underscores its potential impact and makes Targepeutics eligible for a Priority Review Voucher (PRV), which could expedite regulatory review and further support clinical development. The Yuvaan Tiwari Foundation, created in memory of Yuvaan Tiwari who lost his life to Diffuse Midline Glioma (DMG) at the age of 3, is committed to accelerating breakthrough research and clinical solutions for pediatric brain cancer. "We lost our son to this disease, and we know what's at stake. This is more than an investment — it's a direct action toward changing the outlook for children with DMG," said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. "Our foundation is proud to support Targepeutics' bold and innovative treatment approach. This investment reflects our focus on advancing therapies with real potential to impact the lives of children facing this devastating disease." Targepeutics remains focused on pushing the boundaries of what's possible in pediatric oncology, and this new partnership brings it one step closer to delivering transformative care to the patients who need it most. About Targepeutics Targepeutics has an intellectual property portfolio including several issued patents and additional patents pending, focused on novel targeted oncology therapeutics and diagnostics. The company has been awarded Rare Pediatric Disease Designation for GB13 which complements the Orphan Drug Designation for malignant gliomas. The company is completing the required preclinical activities and expects to file an IND for a pediatric first-in-human clinical trial in 1st quarter of 2026. ( About Yuvaan Tiwari Foundation The Yuvaan Tiwari Foundation was established in 2021 by Parvati and Satya Tiwari to honor the legacy of their son Yuvaan (Yuvi). At age two, Yuvi was diagnosed with an aggressive and fatal brain tumor called diffuse midline glioma (DMG). Yuvi fought DMG bravely for seven months. The Yuvaan Tiwari Foundation accelerates high-impact research to find a cure for DMGs and other fatal pediatric brain cancers, while supporting patients and families along their journey. ( View source version on Contacts Sil LutkewittePresidentslutkewitte@
